Kazuhisa Tsuchida

Sapporo, 0600062, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.

Journal: Pharmaceutics

Published: July 26, 2023

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study.

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study.

Journal: Pharmaceutics

Published: May 06, 2023

Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?

Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?

Journal: Endocrine journal

Published: November 25, 2021

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function.

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function.

Journal: Scientific reports

Published: November 17, 2021

Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in db/db mice.

Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in db/db mice.

Journal: Diabetes, obesity & metabolism

Published: July 29, 2021

Glucokinase is required for high-starch diet-induced β-cell mass expansion in mice.

Glucokinase is required for high-starch diet-induced β-cell mass expansion in mice.

Journal: Journal of diabetes investigation

Published: October 23, 2020

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.

Journal: Journal of diabetes investigation

Published: September 29, 2020

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.

Journal: Journal of diabetes investigation

Published: August 25, 2020

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).

Journal: Diabetes, obesity & metabolism

Published: June 23, 2019

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial.

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial.

Journal: Diabetes & metabolism journal

Published: May 15, 2019

Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab.

Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab.

Journal: Journal of diabetes investigation

Published: January 08, 2019

Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment.

Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment.

Journal: Frontiers in endocrinology

Published: April 20, 2018

Showing 1-12 of 12

Last Updated: 09/26/2026